GlobeNewswire

NTT Security and ThreatQuotient Partner to Deliver Threat Intelligence Services

Dela

Collaboration will deliver enhanced threat intelligence capabilities to worldwide managed security clients

TOKYO, Feb. 14, 2018 (GLOBE NEWSWIRE) -- NTT Security, the specialized security company of NTT Group, has announced a partnership with ThreatQuotient to broaden its threat intelligence capabilities. ThreatQuotient's threat intelligence platform (TIP), ThreatQ, will serve as the cornerstone of NTT Security's new threat intelligence services offering.

The platform's flexible architecture for aggregating and correlating threat data will enhance NTT Security capabilities for bringing detailed, relevant threat intelligence to NTT Group clients through managed security services around the world.

NTT Security and NTT Group's operating companies Dimension Data, NTT Communications and NTT DATA, as well as their clients, provide a wealth of visibility into the methods of malicious actors on the internet. Analysts from NTT Security's Global Threat Intelligence Centers (GTIC) will be using ThreatQ to process this data and turn it into actionable threat intelligence that can benefit its consulting and managed services clients.

ThreatQ will also fully integrate into NTT Security's Global Managed Security Services Platform (GMSSP). This will enable NTT Security not only to collect data about attacks on client systems and disseminate the resulting threat intelligence to the Advanced Analytics Engine and expert SOC analysts, but also respond to and proactively stop these attacks in real-time. Many of NTT Group's enterprise clients also have their own in-house threat intelligence capabilities generating data they are willing to share and collaborate with partners. By integrating internal client data with NTT Security's intelligence within ThreatQ, NTT Security will have more context to better protect the managed systems.

NTT Security will also be using the ThreatQ platform to enhance its consulting services. Many standard security services, such as risk assessments, forensic and incident response engagements, penetration tests and red team engagements, will benefit from threat intelligence that can be applied to existing security processes in a way that allows the data to be used immediately. Additionally, NTT Security provides reputation threat services to help clients understand the threats they are facing. ThreatQ makes it possible to search for contextual threat intelligence that is relevant to each unique industry and organization, and prioritize that intelligence for improved security operations.

"NTT Security's global managed security services and channel program is exactly the type of model that we strive to be part of as we work to reach more organizations that need deeper support to get a threat intelligence program off the ground, or get more value out of existing strategies," said Matt McCormick, SVP Business and Corporate Development, ThreatQuotient. "ThreatQuotient is proud to partner with NTT Security to enable more clients to realize the benefits and potential of threat intelligence to accelerate security operations."

ThreatQ uses the standard STIX/TAXII1 protocols for communicating threat data to other security devices, which will allow NTT Group's clients to consume threat intelligence generated by the GTIC. This capability can be used to provide data to a client's own in-house threat intelligence teams via its own TIP or send it directly to security infrastructure, including Security Information and Event Management (SIEM) platforms, ticketing systems, network security devices and endpoints.

Steven Bullitt, Global VP Threat Intelligence and Incident Response at NTT Security, commented: "Our partnership with ThreatQuotient is designed to help NTT Group clients proactively protect themselves based on the real-world threats they face every day. ThreatQ's built-in integration with many of the leading threat intelligence sources as well as NTT's own detecting and collecting threat intelligence will also enable us and these clients to get the data we need. Meanwhile, the flexible deployment options for ThreatQ will also help clients who want to build out their own capabilities."

Having accurate and timely threat intelligence is increasingly important to protect enterprise organizations from sophisticated attackers, but effective threat intelligence is a matter of quality data over sheer quantity. NTT Security's combination of ThreatQ as an industry-leading TIP, with the extensive experience of the human analysis in the GTIC and the machine learning capabilities of the Advanced Analytics Engine in GMSSP, provides a cutting-edge solution for getting the right information where it needs to be, at the right time.

Notes for editors:

1  STIX (Structured Threat Information Expression) / TAXII (Trusted Automated Exchange of Indicator Information)

About NTT Security
NTT Security is the specialized security company and the center of excellence in security for NTT Group.  With embedded security we enable NTT Group companies (Dimension Data, NTT Communications and NTT DATA) to deliver resilient business solutions for clients' digital transformation needs.  NTT Security has multiple SOCs, seven R&D centers, over 1,500 security experts and handles hundreds of thousands of security incidents annually across six continents.

NTT Security ensures that resources are used effectively by delivering the right mix of Managed Security Services, Security Consulting Services and Security Technology for NTT Group companies - making best use of local resources and leveraging our global capabilities.  NTT Security is part of the NTT Group (Nippon Telegraph and Telephone Corporation), one of the largest ICT companies in the world.  Visit nttsecurity.com to learn more about NTT Security or visit www.ntt.co.jp/index_e.html to learn more about NTT Group. 

For sales enquiries, please visit
dimensiondata.comwww.ntt.com/en/index.htmlwww.nttdata.com/global/en/ or speak to your NTT account representative for more information.

About ThreatQuotient
ThreatQuotient(TM) understands that the foundation of intelligence-driven security is people. The company's open and extensible threat intelligence platform, ThreatQ(TM), empowers security teams with the context, prioritization and automation needed to make better decisions, accelerate detection and response and advance team collaboration. Leading global companies use ThreatQ as the cornerstone of their threat operations and management system, increasing security effectiveness and efficiency. ThreatQuotient is headquartered in Northern Virginia with European operations based out of the UK and France. For more information, visit https://threatquotient.com

For more information, please contact:

NTT Security
Origin Communications
t. +44 (0)20 3814 2940
e. nttsecurity@origincomms.com

ThreatQuotient
Taylor Hadley
t. +1 (0)978-877-2113
e. taylor@golaunchtech.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NTT Security (UK) Ltd via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Arcomas CFO lämnar bolaget21.2.2019 23:50:00Pressmeddelande

Arcomas CFO, AnnaPia Johansson har valt att avsluta sin tjänst för nya utmaningar utanför Arcoma. AnnaPia arbetar oförändrat vidare i sin nuvarande tjänst fram till augusti månad eller tills att en ersättare har rekryterats. "Jag vill tacka AnnaPia för hennes ambitiösa arbete för Arcoma och samtidigt önska henne lycka i framtida utmaningar " säger Jesper Söderqvist, VD Arcoma. Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade i hela världen. Arcoma är listat på Nasdaq First North. Certified Advi

Corline Biomedical AB offentliggör bokslutskommuniké för räkenskapsåret 201821.2.2019 08:45:00Pressmeddelande

Corline Biomedical AB ("Corline") publicerar härmed bokslutskommuniké för det fjärde kvartalet och räkenskapsåret 2018. Nedan följer en kort sammanfattning. Fullständig bokslutskommuniké finns tillgänglig på Corlines hemsida (www.corline.se) samt som bifogad fil. VD Henrik Nittmar kommenterar "2018 blev ett genombrottsår för Corline då bolaget gick från preklinisk till klinisk fas i utvecklingen av Renaparin® i och med att RENAPAIR 01-studien öppnade för rekrytering. Nu koncentrerar vi utvecklingsresurserna på att planera inför den värdehöjande fas 2- och fas 3-utvecklingen. Jämfört med branschkollegor har Corline en särskilt gynnsam position i och med att bolaget står på flera ben och parallellt arbetar mot lansering tillsammans med kunder inom medicinteknikområdet. Ett spännande 2019 stundar." Väsentliga händelser under det fjärde kvartalet 2018 Den vetenskapliga tidskriften Transplantation publicerar resultat från den prekliniska utvecklingen av Renaparin®. Här visas i stordjursmode

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum